Optinose (OPTN) Price & Analysis

Compare

461 Followers

OPTN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.82 - $20.03

Previous CloseN/A

Volume6.27K

Average Volume (3M)N/A

Market Cap

$97.22M

Enterprise Value$162.44M

Total Cash (Recent Filing)$73.68M

Total Debt (Recent Filing)$131.75M

Price to Earnings (P/E)―

Beta1.47

Next Earnings

Aug 07, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.92

Shares Outstanding41,436,000

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.67

Enterprise Value/Revenue1.98

Enterprise Value/Gross Profit2.19

Enterprise Value/Ebitda679.68

Forecast

1Y Price Target

$9.00

Price Target Upside-6.25% Downside

Rating ConsensusHold

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Acquisition ImpactThe acquisition of OptiNose by Paratek Pharmaceuticals reflects a 50% premium to OptiNose's previous closing trading price, indicating a positive financial outlook.

Market ExpansionThe approval of an sNDA expands the addressable market by 3x and alleviates payer challenges, significantly increasing the total addressable market compared to XHANCE’s original opportunity.

Revenue GrowthThe company reported a significant revenue growth of 24% year-over-year, exceeding consensus expectations.

Bears Say

Rating DowngradeThe rating for OptiNose has been changed to Neutral and the price target reduced, reflecting adjustments in light of the announced acquisition.

Share Price MovementOPTN shares have drifted significantly since the 3Q24 report, perhaps contributing to the price the Company was able to command from Paratek.

Stock DelistingOptiNose’s common stock is to be delisted from NASDAQ with the expected acquisition closing.

Optinose News

Optinose Acquired by Paratek Pharmaceuticals for $330 Million

Optinose ( ($OPTN) ) has provided an update. Optinose, a company involved in the pharmaceutical industry, has undergone...

3M ago

OPTN

Paratek Pharmaceuticals completes acquisition of Optinose

Paratek Pharmaceuticals, announced that the Company has completed its acquisition of Optinose (OPTN). This acquisition broadens Paratek’s commercial...

3M ago

OPTN

Hold Rating for Optinose Amid Acquisition Uncertainty and Financial Concerns

Optinose (OPTN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

3M ago

OPTN

Optinose Stockholders Approve Merger with Paratek

Optinose ( ($OPTN) ) just unveiled an update. On May 16, 2025, OptiNose, Inc. held a special meeting...

3M ago

OPTN

Optinose Reports Revenue Growth Amid Financial Challenges

Optinose ( ($OPTN) ) has released its Q4 earnings. Here is a breakdown of the information Optinose presented...

4M ago

OPTN

Optinose reports Q4 EPS (3c) vs ($1.33) last year

Reports Q4 revenue $22.418M, consensus $20.82M. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

5M ago

OPTN

Optinose downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Optinose (OPTN) to Neutral from Buy with a $9 price target after Paratek Pharmaceuticals announced...

5M ago

OPTN

Optinose downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler downgraded Optinose (OPTN) to Neutral from Overweight with a $9 price target after Paratek Pharmaceuticals announced...

5M ago

OPTN

Hold Rating Issued Amid Optinose Acquisition by Paratek Pharmaceuticals with Adjusted Price Target

In a report released today, Thomas Flaten from Lake Street downgraded Optinose (OPTN – Research Report) to a...

5M ago

OPTN

Optinose downgraded to Hold from Buy at Lake Street

Lake Street downgraded Optinose (OPTN) to Hold from Buy with a price target of $9, down from $17,...

5M ago

OPTN

Paratek Pharmaceuticals to acquire Optinose in $330M transaction

Paratek Pharmaceuticals (PRTK) and Optinose (OPTN) announced they have entered into a definitive merger agreement under which Paratek...

5M ago

OPTN

OptiNose trading resumes

09:35 EST OptiNose (OPTN) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking...

5M ago

OPTN

OptiNose trading halted, volatility trading pause

09:30 EST OptiNose (OPTN) trading halted, volatility trading pause Published first on TheFly – the ultimate source for...

5M ago

OPTN

OPTN Earnings this Week: How Will it Perform?

Optinose (OPTN) is scheduled to report 4th quarter earnings on 03/06/2025. Regarding Q4 estimates, Wall Street analysts expect...

5M ago

OPTN

OPTN FAQ

What was Optinose’s price range in the past 12 months?

Optinose lowest stock price was $4.82 and its highest was $20.02 in the past 12 months.

What is Optinose’s market cap?

Optinose’s market cap is $97.22M.

When is Optinose’s upcoming earnings report date?

Optinose’s upcoming earnings report date is Aug 07, 2025 which is yesterday.

How were Optinose’s earnings last quarter?

Currently, no data Available

Is Optinose overvalued?

According to Wall Street analysts Optinose’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Optinose pay dividends?

Optinose does not currently pay dividends.

What is Optinose’s EPS estimate?

Optinose’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Optinose have?

Optinose has 41,436,000 shares outstanding.

What happened to Optinose’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Optinose?

Currently, no hedge funds are holding shares in OPTN

Optinose Stock Smart Score

Neutral

Fundamentals

Return on Equity

75.79%

Trailing 12-Months

Asset Growth

37.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Optinose

Optinose (OPTN) is a specialty pharmaceutical company focused on developing and commercializing innovative products for patients treated by ear, nose, and throat (ENT) and allergy specialists. The company's core product, XHANCE, is a nasal spray designed to treat chronic rhinosinusitis with nasal polyps in adults. Optinose operates primarily within the healthcare and pharmaceutical sectors, leveraging its proprietary Exhalation Delivery System to provide effective treatments for ENT conditions.

Optinose (OPTN) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

OPTN Stock 12 Month Forecast

Average Price Target

$9.00

▼(-6.25% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","29":"$29","10.25":"$10.25","16.5":"$16.5","22.75":"$22.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,10.25,16.5,22.75,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Nov<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.39,9.360000000000001,9.33,9.3,9.27,9.24,9.21,9.18,9.15,9.120000000000001,9.09,9.06,9.03,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.39,9.360000000000001,9.33,9.3,9.27,9.24,9.21,9.18,9.15,9.120000000000001,9.09,9.06,9.03,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.39,9.360000000000001,9.33,9.3,9.27,9.24,9.21,9.18,9.15,9.120000000000001,9.09,9.06,9.03,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.85,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.68,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.9,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.65,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.62,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.81,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Similar Stocks

GALT

Galectin Therapeutics

―

BDTX

Black Diamond Therapeutics

―

VOR

Vor Biopharma

―

Compare OPTN Stocks >